MedTrace Logo

Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years

NCT00825162 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1992

Last updated 2018-05-23

Study results available
· View outcomes & findings →

Summary

A Phase IV, Open Label, Multi-Centre Study to Evaluate the Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine in a Paediatric Population Aged \>= 6 Months to \< 18 Years

Conditions

Interventions

BIOLOGICAL

CSL Limited Influenza Virus Vaccine

Single or two-vaccination regimen (0.25mL)

BIOLOGICAL

CSL Limited Influenza Virus Vaccine

Single or two-vaccination regimen (0.5mL)

BIOLOGICAL

CSL Limited Influenza Virus Vaccine

Single vaccination regimen (0.5mL)

Sponsors & Collaborators

  • Seqirus

    lead INDUSTRY

Principal Investigators

  • Stephen Lambert, Dr · Royal Children's Hospital, Brisbane, Herston, QLD, Australia

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825162 on ClinicalTrials.gov